Objective: This study was planned to adapt the Vaccine Hesitancy Scale to Turkish and evaluate its validity and reliability.
Material And Methods: This research was conducted methodologically. The sample of the study consisted of 317 individuals from the patient relatives in the waiting rooms, who have children between the ages 9-16, who applied to the Suleyman Demirel University Hospital policlinic in December 2019. A questionnaire developed by the researcher and the Vaccine Hesitancy Scale were used as data collection tools.
Results: Explanatory factor analysis and confirmatory factor analysis methods were used to evaluate the validity and reliability of the Vaccine Hesitancy Scale. In the Vaccine Hesitancy Scale, the Kaiser-Mayer-Olkin coefficient was 0.897 and the Bartlett test's chi-square value was 1319.67 and the result was significant (P <0.001). Considering the factor loads of the items, it varies between 0.608 and 0.845. As a result of the explanatory factor analysis, it was seen that the scale consists of two factors. This finding is consistent with the original form of the scale. The internal consistency coefficient of the scale was found to be 0.86.
Conclusion: As a result of the validity and reliability analysis, the Vaccine Hesitancy Scale was found to be a valid and reliable scale for the Turkish society, which consists of 9 items and 2 sub-dimensions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152645 | PMC |
http://dx.doi.org/10.5152/TurkArchPediatr.2021.20028 | DOI Listing |
Trans R Soc Trop Med Hyg
December 2024
Department of Health Policy and Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN 37203, USA.
Background: There is a dearth of information regarding mpox risk perception and vaccine acceptance among people living with human immunodeficiency virus (HIV), especially in countries with a dual burden of HIV and mpox, such as Nigeria.
Methods: We used an explanatory mixed methods design and structured questionnaires administered to a clinic-based sample of people living with HIV (n=430), followed by in-depth interviews with a purposive subsample (n=20). Data were analysed using binary logistic regression and the framework approach.
Ann Med
December 2025
Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada.
Background: Despite high COVID-19 vaccine coverage in Canada, vaccine acceptance and preferred delivery among newcomers, racialized persons, and those who primarily speak minority languages are not well understood. This national study explores COVID-19 vaccine acceptance, access to vaccines, and delivery preferences among ethnoculturally diverse population groups.
Methods: We conducted two national cross-sectional surveys during the pandemic (Dec 2020 and Oct-Nov 2021).
Pharmacy (Basel)
December 2024
CSL Seqirus, Summit, NJ 07901, USA.
Background: Recommendations from a trusted healthcare provider have been shown to be the most effective intervention for encouraging patients to be vaccinated. However, providers have reported feeling less prepared to address vaccination questions and having less time to discuss vaccines with patients than before the COVID-19 pandemic. Providers may benefit from a brief update about the available influenza vaccines and vaccination guidelines.
View Article and Find Full Text PDFCureus
November 2024
Family and Community Medicine, King Faisal University, Al-Ahsaa, SAU.
Vaccination is a cornerstone of public health, providing immunity against various diseases. However, vaccine hesitancy, as defined by the World Health Organization (WHO), poses a significant challenge to global health efforts. This cross-sectional study explores the prevalence and determinants of vaccine hesitancy among 401 students at King Faisal University.
View Article and Find Full Text PDFTrop Doct
December 2024
Associate Professor, Department of Microbiology, All India Institute of Medical Sciences, Bathinda, India.
Vaccine hesitancy, anti-Vax campaigners and misinformation hound the administration of vaccines. Our study, conducted at Malwa region of the Punjab, India, was systematically carried out to look for adverse neurological effects after COVID-19 vaccination, given to 1000 people (>18 years and <60 years) who had received either single or multiple doses. No major neurological complications were found; the only side-effect was a transitory headache in 15% of the participants.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!